Search research articles
Contact Us
Filters
Showing results (31-40 of 77) with videos related to
Page
of 8
Sort By:
Proceedings of the National Academy of Sciences of the United States of America
|
June 6, 2012
Cold but not sympathomimetics activates human brown adipose tissue in vivo
Aaron M Cypess, Yih-Chieh Chen, Cathy Sze, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 20, 2025
Hematological Response to Frontline Treatment in Lower Risk Myelodysplastic Syndromes (LRMDS) is Associated With Better Overall Survival
Rami S Komrokji, Muhammad Ammad-Ud-Din, Najla H Al Ali, et al.
Leukemia
|
November 2, 2020
PTPN11 mutations are associated with poor outcomes across myeloid malignancies
David M Swoboda, Najla Al Ali, Onyee Chan, et al.
Annals of Hematology
|
April 18, 2024
Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML
Akriti G Jain, Quinto Gesiotto, Somedeb Ball, et al.
Haematologica
|
February 1, 2024
Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia
Akriti G Jain, Somedeb Ball, Luis Aguirre, et al.
Leukemia
|
May 5, 2023
Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes
Luis E Aguirre, Najla Al Ali, David A Sallman, et al.
Leukemia Research
|
May 15, 2020
Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy
Chetasi Talati, Aaron D Goldberg, Amanda Przespolewski, et al.
Blood Neoplasia
|
June 2, 2025
Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm
Zhuoer Xie, Najla Al Ali, Ling Zhang, et al.
Blood Advances
|
February 16, 2021
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes
Anthony M Hunter, Rami S Komrokji, Seongseok Yun, et al.
Blood Neoplasia
|
June 3, 2026
CMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML?
Rami S Komrokji, Zena Komrokji, Najla H Al Ali, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 77) with videos related to
Sort By:
Page
of 8
Proceedings of the National Academy of Sciences of the United States of America
|
June 6, 2012
Cold but not sympathomimetics activates human brown adipose tissue in vivo
Aaron M Cypess, Yih-Chieh Chen, Cathy Sze, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 20, 2025
Hematological Response to Frontline Treatment in Lower Risk Myelodysplastic Syndromes (LRMDS) is Associated With Better Overall Survival
Rami S Komrokji, Muhammad Ammad-Ud-Din, Najla H Al Ali, et al.
Leukemia
|
November 2, 2020
PTPN11 mutations are associated with poor outcomes across myeloid malignancies
David M Swoboda, Najla Al Ali, Onyee Chan, et al.
Annals of Hematology
|
April 18, 2024
Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML
Akriti G Jain, Quinto Gesiotto, Somedeb Ball, et al.
Haematologica
|
February 1, 2024
Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia
Akriti G Jain, Somedeb Ball, Luis Aguirre, et al.
Leukemia
|
May 5, 2023
Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes
Luis E Aguirre, Najla Al Ali, David A Sallman, et al.
Leukemia Research
|
May 15, 2020
Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy
Chetasi Talati, Aaron D Goldberg, Amanda Przespolewski, et al.
Blood Neoplasia
|
June 2, 2025
Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm
Zhuoer Xie, Najla Al Ali, Ling Zhang, et al.
Blood Advances
|
February 16, 2021
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes
Anthony M Hunter, Rami S Komrokji, Seongseok Yun, et al.
Blood Neoplasia
|
June 3, 2026
CMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML?
Rami S Komrokji, Zena Komrokji, Najla H Al Ali, et al.
Page
of 8